After six cycles of CHOP therapy, CD20 %, PD-L1+CD20+ %, and PD-1+CD20+ % were significantly lower in post-therapy patients than pre-therapy ones, suggesting that peripheral CD20 may have a role in detecting post-therapy DLBCL patients. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.